PHAR, in collaboration with Prothena, published findings from a modified Delphi panel summarizing expert clinical consensus on healthcare utilization among advanced and non-advanced AL amyloidosis patients. Experts estimated advanced patients, who would not be good candidates for hematopoietic stem cell transplant, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. Experts concluded that the development of new treatment options to facilitate organ recovery and improve function may lead to decreased utilization. The full manuscript detailing the methods and findings are published in ClinicoEconomics and Outcomes Research, or can be found on the PHAR publications page.